These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

672 related items for PubMed ID: 33342055

  • 1. Molecular profiling of long-term responders to immune checkpoint inhibitors in advanced non-small cell lung cancer.
    Frigola J, Navarro A, Carbonell C, Callejo A, Iranzo P, Cedrés S, Martinez-Marti A, Pardo N, Saoudi-Gonzalez N, Martinez D, Jimenez J, Sansano I, Mancuso FM, Nuciforo P, Montuenga LM, Sánchez-Cespedes M, Prat A, Vivancos A, Felip E, Amat R.
    Mol Oncol; 2021 Apr; 15(4):887-900. PubMed ID: 33342055
    [Abstract] [Full Text] [Related]

  • 2. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
    Shi Y, Lei Y, Liu L, Zhang S, Wang W, Zhao J, Zhao S, Dong X, Yao M, Wang K, Zhou Q.
    Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
    [Abstract] [Full Text] [Related]

  • 3. Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer.
    Di Federico A, Alden SL, Smithy JW, Ricciuti B, Alessi JV, Wang X, Pecci F, Lamberti G, Gandhi MM, Vaz VR, Spurr LF, Sholl LM, Pfaff KL, Rodig SJ, Li YY, Cherniack AD, Nishino M, Johnson BE, Awad MM.
    Ann Oncol; 2024 Oct; 35(10):902-913. PubMed ID: 38950679
    [Abstract] [Full Text] [Related]

  • 4. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
    Negrao MV, Skoulidis F, Montesion M, Schulze K, Bara I, Shen V, Xu H, Hu S, Sui D, Elamin YY, Le X, Goldberg ME, Murugesan K, Wu CJ, Zhang J, Barreto DS, Robichaux JP, Reuben A, Cascone T, Gay CM, Mitchell KG, Hong L, Rinsurongkawong W, Roth JA, Swisher SG, Lee J, Tsao A, Papadimitrakopoulou V, Gibbons DL, Glisson BS, Singal G, Miller VA, Alexander B, Frampton G, Albacker LA, Shames D, Zhang J, Heymach JV.
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
    [Abstract] [Full Text] [Related]

  • 5. Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.
    Alborelli I, Leonards K, Rothschild SI, Leuenberger LP, Savic Prince S, Mertz KD, Poechtrager S, Buess M, Zippelius A, Läubli H, Haegele J, Tolnay M, Bubendorf L, Quagliata L, Jermann P.
    J Pathol; 2020 Jan; 250(1):19-29. PubMed ID: 31471895
    [Abstract] [Full Text] [Related]

  • 6. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y, Zeng D, Ou Q, Liu S, Li A, Chen Y, Lin D, Gao Q, Zhou H, Liao W, Yao H.
    JAMA Netw Open; 2019 Jul 03; 2(7):e196879. PubMed ID: 31290993
    [Abstract] [Full Text] [Related]

  • 7. Comprehensive assessment of PD-L1 expression, tumor mutational burden and oncogenic driver alterations in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
    Yoh K, Matsumoto S, Furuya N, Nishino K, Miyamoto S, Oizumi S, Okamoto N, Itani H, Kuyama S, Nakamura A, Nishi K, Fukuda I, Tsuta K, Hayashi Y, Motoi N, Ishii G, Goto K.
    Lung Cancer; 2021 Sep 03; 159():128-134. PubMed ID: 34333203
    [Abstract] [Full Text] [Related]

  • 8. Dual Biomarker Combining DNA Damage Repair Gene Mutations and PD-L1 Expression for Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer.
    Kim H, Lim DH, Kwon YS, Kim MA, Park KU.
    Anticancer Res; 2023 May 03; 43(5):2343-2349. PubMed ID: 37097676
    [Abstract] [Full Text] [Related]

  • 9. Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencing.
    Kim HS, Cha H, Kim J, Park WY, Choi YL, Sun JM, Ahn JS, Ahn MJ, Park K, Lee SH.
    Eur J Cancer; 2019 Oct 03; 120():65-74. PubMed ID: 31493723
    [Abstract] [Full Text] [Related]

  • 10. Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.
    Rizvi H, Sanchez-Vega F, La K, Chatila W, Jonsson P, Halpenny D, Plodkowski A, Long N, Sauter JL, Rekhtman N, Hollmann T, Schalper KA, Gainor JF, Shen R, Ni A, Arbour KC, Merghoub T, Wolchok J, Snyder A, Chaft JE, Kris MG, Rudin CM, Socci ND, Berger MF, Taylor BS, Zehir A, Solit DB, Arcila ME, Ladanyi M, Riely GJ, Schultz N, Hellmann MD.
    J Clin Oncol; 2018 Mar 01; 36(7):633-641. PubMed ID: 29337640
    [Abstract] [Full Text] [Related]

  • 11. Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels.
    Ricciuti B, Wang X, Alessi JV, Rizvi H, Mahadevan NR, Li YY, Polio A, Lindsay J, Umeton R, Sinha R, Vokes NI, Recondo G, Lamberti G, Lawrence M, Vaz VR, Leonardi GC, Plodkowski AJ, Gupta H, Cherniack AD, Tolstorukov MY, Sharma B, Felt KD, Gainor JF, Ravi A, Getz G, Schalper KA, Henick B, Forde P, Anagnostou V, Jänne PA, Van Allen EM, Nishino M, Sholl LM, Christiani DC, Lin X, Rodig SJ, Hellmann MD, Awad MM.
    JAMA Oncol; 2022 Aug 01; 8(8):1160-1168. PubMed ID: 35708671
    [Abstract] [Full Text] [Related]

  • 12. High levels of chromosomal aberrations negatively associate with benefit to checkpoint inhibition in NSCLC.
    Frigola J, Carbonell C, Irazno P, Pardo N, Callejo A, Cedres S, Martinez-Marti A, Navarro A, Soleda M, Jimenez J, Hernandez-Losa J, Vivancos A, Felip E, Amat R.
    J Immunother Cancer; 2022 Apr 01; 10(4):. PubMed ID: 35477861
    [Abstract] [Full Text] [Related]

  • 13. UBE3A deletion enhances the efficiency of immunotherapy in non-small-cell lung cancer.
    Zhang N, Shen J, Gou L, Cao M, Ding W, Luo P, Zhang J.
    Bioengineered; 2022 May 01; 13(5):11577-11592. PubMed ID: 35531878
    [Abstract] [Full Text] [Related]

  • 14. Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer.
    Jiang J, Jin Z, Zhang Y, Peng L, Zhang Y, Zhu Z, Wang Y, Tong D, Yang Y, Wang J, Yang Y, Xiao K.
    Front Immunol; 2021 May 01; 12():646874. PubMed ID: 33927719
    [Abstract] [Full Text] [Related]

  • 15. Tumor mutational burden as a predictive biomarker for non-small cell lung cancer treated with immune checkpoint inhibitors of PD-1/PD-L1.
    Shao MM, Xu YP, Zhang JJ, Mao M, Wang MC.
    Clin Transl Oncol; 2024 Jun 01; 26(6):1446-1458. PubMed ID: 38190035
    [Abstract] [Full Text] [Related]

  • 16. Immune related endonucleases and GTPases are not associated with tumor response in patients with advanced non-small cell lung cancer treated with checkpoint inhibitors.
    Ramdani HO, Falk M, Heukamp LC, Schatz S, Tiemann M, Wesseler C, Diehl L, Schuuring E, Groen HJM, Griesinger F.
    Pathol Res Pract; 2021 Nov 01; 227():153651. PubMed ID: 34673351
    [Abstract] [Full Text] [Related]

  • 17. Comparison of the Predictive Power of a Combination versus Individual Biomarker Testing in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors.
    Kim H, Kwon HJ, Kim ES, Kwon S, Suh KJ, Kim SH, Kim YJ, Lee JS, Chung JH.
    Cancer Res Treat; 2022 Apr 01; 54(2):424-433. PubMed ID: 34237208
    [Abstract] [Full Text] [Related]

  • 18. Sequential ctDNA whole-exome sequencing in advanced lung adenocarcinoma with initial durable tumor response on immune checkpoint inhibitor and late progression.
    Giroux Leprieur E, Hélias-Rodzewicz Z, Takam Kamga P, Costantini A, Julie C, Corjon A, Dumenil C, Dumoulin J, Giraud V, Labrune S, Garinet S, Chinet T, Emile JF.
    J Immunother Cancer; 2020 Jun 01; 8(1):. PubMed ID: 32581058
    [Abstract] [Full Text] [Related]

  • 19. Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer.
    Thummalapalli R, Ricciuti B, Bandlamudi C, Muldoon D, Rizvi H, Elkrief A, Luo J, Alessi JV, Pecci F, Lamberti G, Di Federico A, Hong L, Zhang J, Heymach JV, Gibbons DL, Plodkowski AJ, Ravichandran V, Donoghue MTA, Vanderbilt C, Ladanyi M, Rudin CM, Kris MG, Riely GJ, Chaft JE, Hellmann MD, Vokes NI, Awad MM, Schoenfeld AJ.
    Clin Cancer Res; 2023 Nov 01; 29(21):4408-4418. PubMed ID: 37432985
    [Abstract] [Full Text] [Related]

  • 20. HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients.
    Shim JH, Kim HS, Cha H, Kim S, Kim TM, Anagnostou V, Choi YL, Jung HA, Sun JM, Ahn JS, Ahn MJ, Park K, Park WY, Lee SH.
    Ann Oncol; 2020 Jul 01; 31(7):902-911. PubMed ID: 32320754
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.